Helus Pharma will present topline results from its Phase 3 APPROACH study evaluating HLP003 as an adjunctive treatment for major depressive disorder on November 16, 2026. This drug has received Breakthrough Therapy Designation from the FDA, highlighting its potential significance in mental health treatment. The company will host a webcast to share these results, which could impact future treatment options for depression. Investors and stakeholders are watching closely for the study's outcome, which may influence Helus Pharma's development and commercialization plans.
Helus Pharma's upcoming Phase 3 results presentation is noted here alongside Pluang's health sector market snapshot as of Nov 16, 2026 00:01 WIB. Out of 150 priced health-sector US stocks, 71 gained and 77 declined. Among notable movers, AVAH dropped 6.05% to USD 11.50 with a typical hold time of 12 days, contrasting with ABEO which rose 5.68% to USD 2.42 and saw 100% buy order activity with a 22-day hold time, while ALNY increased 5.36% to USD 165.04 with a 41-day hold time.
In Q3 2026, AMG TimesSquare Small Cap Growth Fund outperformed the Russell 2000® Growth Index, driven by strong holdings in Information Technology, Financials, and Consumer Staples sectors. The fund's success was attributed to company-specific fundam...
The Schwab US Dividend Equity ETF (SCHD) has rallied about 10% since early October, supported by stronger earnings from key holdings like Texas Instruments and UnitedHealth, as well as inflows into dividend-focused funds. SCHD trades at roughly 18.6 ...
Eaton Vance Tax-Advantaged Global Dividend Income Fund (ETG) raised its monthly distribution by 23.7%, marking its highest payout since inception. Despite this increase and strong long-term returns, ETG shares trade at a significant discount of over ...
U.S. Treasury Secretary Scott Bessent called for a major overhaul at Nvidia following CEO Jensen Huang's resignation amid allegations of illicit chip sales to China. Bessent urged the company to hire an external CEO and suggested scrutiny of other ex...
Bitcoin fell to $62,081 on Nov. 15, its lowest since mid-July, driven by a weekend selloff and $1.91 billion in net outflows from US spot Bitcoin ETFs over seven days. The decline extends across major cryptocurrencies, with Ether and Solana also drop...
